Stockscreener 앱 받기
4.83
9.52%
0.42
시장 영업 전:
4.90
0.07
+1.45%
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Undervalued Penny Stocks To Watch In May 2026 - simplywall.st
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Nuvation Bio's CEO and CFO line up four investor webcasts in May - Stock Titan
NUVB Stock Rallies As IBTROZI Drives Surprise Profit - StocksToTrade
Nuvation Bio Inc. 2026 Q1 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
A Quick Look at Today's Ratings for Nuvation Bio(NUVB.US), With a Forecast Between $12 to $20 - Moomoo
Nuvation Bio Inc. (NYSE:NUVB) Q1 2026 Earnings Call Transcript - Insider Monkey
Nuvation Bio Falls Short on Q1 2026: $0.01 EPS vs $0.01 Expected - AlphaStreet
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch progress By Investing.com - Investing.com Australia
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch progress - Investing.com
Nuvation Bio Q1 2026 Earnings Call Transcript - MarketBeat
Nuvation Bio Q1 Earnings Call Highlights - Yahoo Finance
Nuvation Bio Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Nuvation Bio Inc. (NUVB) lags Q1 earnings estimates - MSN
NUVB: Ibtrozi's first-line uptake and revenue growth accelerate, supported by strong financials - TradingView
Nuvation Bio (NUVB) Q1 2026 Earnings Transcript - The Globe and Mail
MSN Money - MSN
Earnings call transcript: Nuvation Bio Q1 2026 sees revenue beat, flat EPS - Investing.com
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates - Yahoo Finance
Nuvation Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nuvation Bio Q1 Swings to Profit, Revenue Rise - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Posts Q1 EPS $0.01, vs. FactSet Est of $0.03 Loss - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q1 Revenue $83.2M, Vs. FactSet Est of $65.7M - Moomoo
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Nuvation Bio (NUVB) swings to Q1 profit on $83M taletrectinib revenue - Stock Titan
Nuvation Bio Inc. (NUVB) reports next week: Wall Street expects earnings growth - MSN
Nuvation Bio earnings up next: Can IBTROZI launch momentum continue? By Investing.com - Investing.com South Africa
Nuvation Bio earnings up next: Can IBTROZI launch momentum continue? - Investing.com UK
Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Are options traders betting on a big move in Nuvation Bio stock? - MSN
Earnings Preview: Nuvation Bio to Report Financial Results Post-market on May 04 - Moomoo
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo - MSN
H.C. Wainwright reiterates Nuvation Bio stock rating on NCCN addition - Investing.com UK
H.C. Wainwright reiterates Nuvation Bio stock rating on NCCN addition By Investing.com - Investing.com India
Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade - MSN
Down 24% in 4 weeks, here's why Nuvation Bio (NUVB) looks ripe for a turnaround - MSN
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers - Investing News Network
Nuvation Bio announces National Comprehensive Cancer Network® adds taletrectinib (Ibtrozi®) as recommended option - marketscreener.com
Nuvation Bio (NUVB) Projected to Post Earnings on Monday - MarketBeat
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers - PR Newswire
0.14%
0.48%
자본화:
|
볼륨(24시간):